Herbal extracts for treatment of herpesvirus infections
Disclosed is a formulation comprising at least two of Rheum palmatum, Chrysanthemum indicum and Sanguisorba officinalis extracts or prevalent molecules therefrom and a pharmaceutically acceptable carrier. Further disclosed is a formulation comprising one or more of Rheum palmatum, Chrysanthemum indicum and Sanguisorba officinalis extracts, or prevalent molecules therefrom in combination with acyclovir and a pharmaceutically acceptable carrier. Disclosed also is a method for treating herpesvirus infections by administering a formulation comprising extracts of Rheum palmatum, Chrysanthemum indicum or Sanguisorba officinalis extracts or prevalent molecules therefrom with or without an antiviral agent, such as acyclovir and a pharmaceutically acceptable carrier.
1. A formulation consisting of extracts of Rheum palmatum, Chrysanthemum indicum and Sanguisorba officinalis and a pharmaceutically acceptable carrier in an effective amount to treat a herpesvirus infection and/or prevent diseases resulting therefrom in humans.
2. The formulation of claim 1 , wherein the formulation is a topical formulation.
3. The formulation according to claim 2 , wherein the pH of the formulation is between 4.0 and 7.0.
4. The formulation according to claim 1 , wherein the combined concentration of the herbal extracts in the formulation is between 0.01% w/w and 50% w/w.
5. A method of treating herpesvirus infections and/or preventing diseases resulting from herpesvirus infections, comprising administering the formulation according to claim 1 to a human patient in need thereof.
6. The method according to claim 5 , wherein the formulation is administered once, twice, three or more times a day.
7. The method according to claim 5 , wherein the formulation is administered for one, two, three or more days.
8. The method of claim 5 , wherein the herpesvirus infection is an HSV-1 infection.
9. The method of claim 5 , wherein the herpesvirus infection is an HSV-2 infection.
10. The method of claim 5 , wherein the herpesvirus infection is a VZV infection.
11. The method of claim 5 , further comprising administering the formulation in conjunction with an antiviral agent.
12. The method of claim 11 , wherein the antiviral agent is acyclovir.